GLPwatch
Gastroparesis
Investigational / off-label
Last updated 2026-05-28 15:46 UTCSome GLP-1 drugs, such as exenatide and semaglutide, have been associated with delayed gastric emptying, which may contribute to gastrointestinal effects like gastroparesis, while other studies explore the relationship between GLP-1 receptor activation and pancreatic or gastrointestinal changes.
AI summary of the sources below.
Approved GLP-1 drugs (0)
No GLP-1 drug is FDA-approved for gastroparesis in our data. Any research below reflects investigational or off-label study.
Research (43)
- Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model.
- Semaglutide, delayed gastric emptying, and intraoperative pulmonary aspiration: a case report.
- Liraglutide: short-lived effect on gastric emptying -- long lasting effects on body weight.
- Regulation of gastric emptying rate and its role in nutrient-induced GLP-1 secretion in rats after vertical sleeve gastrectomy.
- The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.
- Association of glucagon-like peptide-1 receptor agonist treatment with gastric residue in an esophagogastroduodenoscopy.
- Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions.
- Influence of semaglutide use on the presence of residual gastric solids on gastric ultrasound: a prospective observational study in volunteers without obesity recently started on semaglutide.
- Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide.
- Allelic variant in the glucagon-like peptide 1 receptor gene associated with greater effect of liraglutide and exenatide on gastric emptying: A pilot pharmacogenetics study.
- Involvement of gut microbiota in association between GLP-1/GLP-1 receptor expression and gastrointestinal motility.
- Effects of the GLP-1 receptor agonist lixisenatide on postprandial glucose and gastric emptying--preclinical evidence.
- Relationship between residual gastric content and peri-operative semaglutide use assessed by gastric ultrasound: a prospective observational study.
- Shorter-acting glucagon-like peptide-1 receptor agonists are associated with increased development of gastro-oesophageal reflux disease and its complications in patients with type 2 diabetes mellitus: a population-level retrospective matched cohort study.
- Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations.
- Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: A randomized, placebo-controlled, double-blind, parallel-group study.
- Physiologically-Based Pharmacokinetic Modeling of Atorvastatin Incorporating Delayed Gastric Emptying and Acid-to-Lactone Conversion.
- Effect of various perioperative semaglutide interruption intervals on residual gastric content assessed by esophagogastroduodenoscopy: A retrospective single center observational study.
- A Scoping Review of GLP-1 Receptor Agonists: Are They Associated with Increased Gastric Contents, Regurgitation, and Aspiration Events?
- Effect of the GLP-1 analog liraglutide on satiation and gastric sensorimotor function during nutrient-drink ingestion.
- Prevalence and variations in gastric emptying delay in response to GLP-1 receptor agonist liraglutide.
- Glucagon-like peptide-1 receptor agonists and impaired gastric emptying: a pharmacovigilance analysis of the US Food and Drug Administration adverse event reporting system.
- Exendin-4, a glucagon-like peptide-1 analogue accelerates healing of chronic gastric ulcer in diabetic rats.
- Intelligent Escape System for the Oral Delivery of Liraglutide: A Perfect Match for Gastrointestinal Barriers.
- Exenatide Delays Gastric Emptying in Patients with Type 2 Diabetes Mellitus but not in Those with Gastroparetic Conditions.
- Suspected Gastroparesis With Concurrent Gastroesophageal Reflux Disease Induced by Low-Dose Liraglutide.
- Effect of lixisenatide on liquid gastric emptying in type 2 diabetes - Implications for the use of GLP-1 receptor agonists before procedures.
- Impact of GLP-1 receptor agonists on upper gastrointestinal endoscopy: an updated systematic review and meta-analysis.
- Evaluation of gastric content in fasting patient during semaglutide use: an observational study.
- The effect of exenatide and erythromycin on postprandial symptoms and their relation to gastric functions.
Common questions
- Which GLP-1 drugs are FDA-approved for Gastroparesis?
- No GLP-1 drug is currently FDA-approved for gastroparesis; any use would be off-label or investigational.
- Is there research on GLP-1 drugs for Gastroparesis?
- GLPwatch tracks 43 research papers on GLP-1 drugs and gastroparesis. This research is investigational and does not imply FDA approval.